GENITOURINARY CANCER
22.0291: A Phase 3, multicenter, randomized study of abiraterone (LY2835219) plus prednisone with or without an investigational product in patients with prostate cancer
Principal Investigator: Rohit Kumar, MD
Phase: III
Description: This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation
ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT03706365?term=NCT03706365&rank=1
22.0978: A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors
Principal Investigator: Rebecca Redman, M.D.
Phase: I
Description: The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.
More Info: https://clinicaltrials.gov/ct2/show/NCT05514444?term=NCT05514444&draw=2&rank=1
22.0891: A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety,tolerability, and pharmacokinetic profile of AB521 monotherapy in participants with clear cellrenal cell carcinoma and other solid tumors
Principal Investigator: Rohit Kumar, MD
Phase: I
Description: This is a multicenter, open-label, Phase 1 study to evaluate the safety, pharmacokinetic (PK), preliminary clinical activity, pharmacodynamic (PD), and biomarkers of AB521 as monotherapy for advanced solid tumor malignancies (dose escalation) and clear cell renal cell carcinoma (ccRCC) (dose expansion).
More Info: https://clinicaltrials.gov/ct2/show/NCT05536141?term=NCT05536141&draw=2&rank=1
20.0130: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer.
Principal Investigator: Vikas Singh, MD
Phase: III
Description: This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.
More info: https://clinicaltrials.gov/ct2/show/NCT03775265?term=NCT03775265&draw=2&rank=1
19.0721: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Principal Investigator: Scott Silva, MD, PhD
Phase: III
Description: This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
More info: https://clinicaltrials.gov/ct2/show/NCT03678025?term=NCT03678025&rank=1
08.0388 - Protocol for the Cancer Database and Specimen Repository (CDSR) at the Brown Cancer Center (Previous Lung Repository).
Principal Investigator: Rebecca Redman, M.D.
Description: The mission of the Cancer Database and Specimen Repository (CDSR) is to collect clinical information and samples of human specimens from cancer patients and from control patients for research, and to distribute specimens to researchers for the advancement of science.